CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Cutting costs during the holiday season can enhance your savings. Explore practical ways to save money while celebrating joyfully.
20,443 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
AI is reshaping business, and a few durable names stand to benefit for years. Here are three artificial intelligence ...
Investors swing between growth and value stocks as markets swing from tech optimism to defensive plays. This guide br...
When vertex stock rising today captures headlines, investors should look beyond the flash. This guide explains the wh...
Axcelis Technologies has seen its stock surge this year, riding AI-chip demand. This guide breaks down what the compa...
Honeywell Aerospace becomes an independent company after the June 29, 2026 spin-off, offering a focused aerospace exp...
A transformative update could reshape Micron stock dynamics. This guide breaks down what the news might mean, how to ...
Investors are noticing a uptick in service now shares as optimism returns to cloud software. This article breaks down...
Morgan Stanley just boosted its payout while re-upping a massive buyback. This article breaks down what the paired di...
In 2026, dividend aristocrats quietly outrunning software stocks has drawn fresh money into income-focused ETFs as vo...
Tesla reports a Q2 delivery surge to 480,126 vehicles, topping forecasts and signaling durable demand despite ongoing...
Michael Burry has added a Micron short, expanding a wager that AI-driven chip stocks may soon pull back. The move com...